Treatment approaches for metastatic Ewing's sarcoma: A review of the literature

Journal of Pediatric Oncology Nursing

Volumn 22, Issue 6, 2005, Pages 339-352

  Hendershot, Eleanor ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b NONE   (Canada)

Author keywords

Chemotherapy; Ewing's sarcoma; Metastatic; PNET; Treatment

Indexed keywords

CASE REPORT; CHILD; EWING SARCOMA; HUMAN; IMMUNOTHERAPY; MALE; METASTASIS; NURSING; ONCOLOGY NURSING; PATHOLOGY; REVIEW; RISK ASSESSMENT; RISK FACTOR; STEM CELL; STEM CELL TRANSPLANTATION;

CHILD; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASM METASTASIS; ONCOLOGIC NURSING; RISK ASSESSMENT; RISK FACTORS; SARCOMA, EWING'S; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 27744536437     PISSN: 10434542     EISSN: None     Source Type: Journal    
DOI: 10.1177/1043454205279300     Document Type: Review

References (43)

1. Ahmed, A., Gilbert-Barness, E., & Lacson, A. (2004). Expression of C-kit in Ewing family of tumors: A comparison of different immunohistochemical protocols. Pediatric and Developmental Pathology, 7(4), 342-347.
2. Burdach, S. (2004). Treatment of advanced Ewing tumors by combined radiochemotherapy and engineered cellular transplants. Pediatric Transplantation, 8(Suppl. 5), 67-82.
3. Burdach, S., & Jurgens, H. (2002). High-dose chemoradiotherapy (HDC) in the Ewing family of tumors (EFT). Critical Reviews in Oncology/Hematology, 41(2), 169-189.
4. Burdach, S., Meyer-Bahlburg, A., Laws, H. J., Haase, R., van Kaik, B., Metzner, B., et al. (2003). High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: Results of two consecutive regimens assessing the role of total-body irradiation. Journal of Clinical Oncology, 21(16), 3072-3078.
5. Burdach, S., van Kaick, B., Laws, H. J., Ahrens, S., Haase, R., Korholz, D., et al. (2000). Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup Study EICESS. Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Annals of Oncology, 11(11), 1451-1462.
6. Cerisano, V., Aalto, Y., Perdichizzi, S., Bernard, G., Manara, M. C., Benini, S., et al. (2004). Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: Actin and zyxin as key intracellular mediators. Oncogene, 23(33), 5664-5674.
7. Dalal, S., Berry, A. M., Cullinane, C. J., Mangham, S., Grimer, R., Lewis, I. J., et al. (2005). Vascular endothelial growth factor: A therapeutic target for tumors of the Ewing's sarcoma family. Clinical Cancer Research, 11(6), 2364-2378.
8. Donaldson, S.S. (2004). Ewing sarcoma: Radiation dose and target. Pediatric Blood and Cancer, 42(5), 471-476.
9. Dunst, J., & Schuck, A. (2004). Role of radiotherapy in Ewing tumors. Pediatric Blood and Cancer, 42(5), 465-470.
10. Folkman, J. (1997). Antiangiogenic therapy. In V. T. Devita, S. Hellman, & S. A. Tosenberg (Eds.), Principles and practice of oncology (pp. 3075-3085). Philadelphia, PA: Lippincott-Raven.
11. Ginsberg, J. P., Woo, S. Y., Johnson, M. E., Hicks, M. J., & Horowitz, M. E. (2002). Ewing's sarcoma family of tumors: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. In P. A. Pizzo & D. G. Poplack (Eds.), Principles and practice of pediatric oncology (4th ed., pp. 973-1016). Philadelphia: Lippincott Williams & Wilkins.
12. Gonzalez, I., Andreu, E. J., Panizo, A., Inoges, S., Fontalba, A., Fernandez-Luna, J. L., et al. (2004). Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clinical Cancer Research, 10(2), 751-761.
13. Grier, H. E., Krailo, M. D., Tarbell, N. J., Link, M. P., Fryer, C. J., Pritchard, D. J., et al. (2003). Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. New England Journal of Medicine, 348(8), 694-701.
14. Hawkins, D. S., Felgenhauer, J., Park, J., Kreissman, S., Thomson, B., Douglas, J., et al. (2002). Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. Cancer, 95(6), 1354-1365.
15. Huang, H. Y., Illei, P. B., Zhao, Z., Mazumdar, M., Huvos, A. G., Healey, J. H., et al. (2005). Ewing sarcomas with p53 mutation or p 16/pARF homozygous deletion: A highly lethal subset associated with poor chemoresponse. Journal of Clinical Oncology, 23(3), 548-558.
16. Kalambakas, S. A., Moore, T. B., & Feig, S. A. (2004). Megatherapy and stem cell transplantation for Ewing's family of tumors: A critical review of current literature. Pediatric Transplantation, 8(Supp. 5), 83-88.
17. Kebudi, R., Gorgun, O., & Ayan, I. (2004). Oral etoposide for recurrent/progressive sarcomas of childhood. Pediatric Blood and Cancer, 42(4), 320-324.
18. Kerbel, R. S. (1997). A cancer therapy resistant to resistance. Nature, 390, 335-336.
19. Kerbel, R. S., Klement, G., Pritchard, K. I., & Kamen, B. (2002). Editorial: Continuous low-dose angiogenic/metronomic chemotherapy: From the research laboratory in to the oncology clinic. Annals of Oncology, 13(1), 12-15.
20. Kolb, E. A., Kushner, B. H., Gorlick, R., Laverdiere, C., Healey, J. H., LaQuaglia, M. P., et al. (2003). Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. Journal of Clinical Oncology, 21(18), 3423-3430.
21. Koscielniak, E., Gross-Wieltsch, U., Treuner, J., Winkler, P., Klingebiel, T., Lang, P., et al. (2005). Graft-versus-Ewing sarcoma effect and long-term remission induced by haploidentical stem-cell transplantation in a patient with relapse of metastatic disease. Journal of Clinical Oncology, 23(1), 242-243.
22. Kushner, B. H., & Meyers, P. A. (2001). How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. Journal of Clinical Oncology, 19(3), 870-880.
23. Ladenstein, R., Lasset, C., Pinkerton, R., Zucker, J. M., Peters, C., Burdach, S., et al. (1995). Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: A report from the EBMT solid tumour registry. Bone Marrow Transplant, 15(5), 697-705.
24. Landuzzi, L., De Giovanni, C., Nicoletti, G., Rossi, I., Ricci, C., Astolfi, A., et al. (2000). The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit. American Journal of Pathology, 157(6), 2123-2131.
25. Lau, L., Supko, J. G., Blaney, S., Hershon, L., Seibel, N., Krailo, M., et al. (2005). A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group Study. Clinical Cancer Research, 11(2 Pt 1), 672-677.
26. Laws, H. J., Burdach, S., van Kaick, B., Engel, B., Dirksen, U., Korholz, D., et al. (1999). Multimodality diagnostics and megatherapy in poor prognosis Ewing's tumor patients. A single-center report [Online]. Strahlentherapie und Onkologie Abstracts, 175(10), 488. (Abstract from Pubmed Item: 10554643)
27. Meyers, P. A., Krailo, M. D., Ladanyi, M., Chan, K. W., Sailer, S. L., Dickman, P. S., et al. (2001). High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. Journal of Clinical Oncology, 19(11), 2812-2820.
28. Miser, J. S., Krailo, M. D., Tarbell, N. J., Link, M. P., Fryer, C. J., Pritchard, D. J., et al. (2004). Treatment of metastatic Ewing's sarcoma ifosfamide and etoposide - A Children's Cancer Group and Pediatric Oncology Group study. Journal of Clinical Oncology, 22(14), 2873-2876.
29. National Cancer Institute. (2003). Ecteinascidin-743 in treating young patients with recurrent or refractory soft tissue sarcoma or Ewing's family of tumors [On-line]. Retrieved from http://www.nci.nih.gov/search/ ViewClinicalTrials.aspx?cdrid=329999&version=patient&protocolsearchid= 1496952
30. National Cancer Institute. (2004). Imatinib Mesylate in treating patients with recurrent Ewing's family of tumors or desmoplastic small round-cell tumor [Online]. Retrieved from http://www.nci.nih.gov/search/ViewClinicalTrials.aspx? cdrid=304551 &version=patient&protocolsearchid=1503373
31. O'Brien, J. M., & Tomlinson, D. (2005). Radiation therapy. In D. Tomlinson & N. E. Kline (Eds.), Pediatric oncology nursing: Advanced clinical handbook. Berlin, Germany: Springer-Verlag.
32. Paulussen, M., Ahrens, S., Burdach, S., Craft, A., Dockhorn-Dworniczak, B., Dunst, J., et al. (1998). Primary metastatic (stage IV) Ewing tumor: Survival analysis of 171 patients from the EICESS studies. Annals of Oncology, 9(3), 275-281.
33. Pietras, K., & Hanahan, D. (2005). A multitargeted, metronomic, and maximum-tolerated dose "Chemo-Switch" regimen is antiangiogenic producing objective responses and survival benefit in a mouse model of cancer. Journal of Clinical Oncology, 23(5), 939-952.
34. Pinkerton, C. R. (1999). Ewing Sarcoma/primitive neuro-ectodermal tumor. In C. R. Pinkerton, A. J. Michalski, & P. A. Veys (Eds.), Clinical challenges in paediatric oncology. Oxford, UK: ISIS Medical Medial LTD.
35. Poon, R. T., Fan, S. T., & Wong, J. (2001). Clinical implications of circulating angiogenic factors in cancer patients. Journal of Clinical Oncology, 19(4), 1207-1225.
36. Rodriguez-Galindo, C., Billups, C. A., Kun, L. E., Pratt, C. B., Merchant, T. E., Santana, V. M., et al. (2002). Survival after recurrence of Ewing tumors. Cancer, 94(2), 561-569.
37. Rodriguez-Galindo, C., Spunt, S., & Pappo, A. S. (2003). Treatment of Ewing sarcoma family of tumors: Current status and outlook for the future. Medical and Pediatric Oncology, 40(5), 276-287 [erratum 41(6), 594].
38. Scappaticci, F. A. (2002). Mechanisms and future directions for angiogenesis-based cancer therapies. Journal of Clinical Oncology, 20(18), 3906-3927.
39. Sebire, N. J., Gibson, S., Rampling, D., Williams, S., Malone, M., & Tamsay, A. D. (2005). Irnmunohistochemical findings in embryonal small round cell tumors with molecular diagnostic confirmation. Applied Immunohistochemistry and Molecular Morphology, 13(1), 1-5.
40. Tanaka, K., Matsunobu, T., Sakamoto, A., Matsuda, S., & Iwamoto, Y. (2002). Journal of Orthopedic Science, 7(4), 477-482.
41. Venkateswaran, L., Rodriguez-Galindo, C., Merchan, T. E., Poquette, C. A., Rao, B. N., & Pappo, A. S. (2001). Primary Ewing tumor of the vertebrae: Clinical characteristics, prognostic factors and outcome. Medical and Pediatric Oncology, 37(1), 30-35.
42. Vietti, T. J., Gehan, E. A., Nesbit, M. E. Jr., Burgert, E. O. Jr., Pilepich, M., Tefft, M., et al. (1981). Multimodal therapy in metastatic Ewing's sarcoma: An Intergroup Study. National Cancer Institute Monographs, 56, 279-284.
43. Whelan, J. S., Burcombe, R. J., Janinis, J., Baldelli, A. M., & Cassoni, A. M. (2002). A systematic review of the role of pulmonary irradiation in the management of primary bone tumours. Annals of Oncology, 13(1), 23-30.